Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
Anika Therapeutics (ANIK) has seen its stock price increase by 43.4% over the past three months, driven by investor confidence in its commercial products, pipeline, and improved financial outlook. The company's diversified portfolio includes osteoarthritis pain management and regenerative solutions, with strong performance in both commercial and OEM channels. Anika has also raised its 2026 financial guidance while adopting a more conservative approach for 2027.
Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why
Anika Therapeutics (NASDAQ:ANIK) stock recently surpassed its 200-day moving average of $14.84, closing at $21.26, despite a 1.4% dip during the session. Analyst sentiment has improved, with B. Riley raising its price target to $21 and Wall Street Zen and Zacks upgrading the stock to "strong buy," resulting in an overall "Moderate Buy" rating. The company also reported strong quarterly earnings, beating expectations with $0.42 EPS on $32.61 million in revenue.
Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO
This article highlights five stocks—OptimumBank Holdings Inc. (OPHC), EuroDry Ltd. (EDRY), Enova International Inc. (ENVA), Anika Therapeutics Inc. (ANIK), and The GEO Group Inc. (GEO)—that have shown recent price strength and are poised to continue their upward momentum. Following a strong performance by major U.S. stock indexes in early August, these companies are identified as having solid reasons for their bull runs and strong expected earnings growth. The article emphasizes using additional parameters beyond just price strength for a successful investment strategy.
Understanding Momentum Shifts in (ANIK)
This article analyzes Anika Therapeutics Inc. (ANIK) using AI models, highlighting strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, alongside a multi-timeframe signal analysis. The report emphasizes the role of AI in providing real-time signals, risk management, and personalized alerts for investors.
Anika Therapeutics, Inc. (ANIK) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial data for Anika Therapeutics, Inc. (ANIK), a company specializing in early intervention orthopedics. It includes current stock price, performance metrics, key statistics, earnings trends, analyst ratings, and a company overview detailing its product offerings in osteoarthritis pain management and regenerative solutions. The stock closed at $21.42, up 6.25%, with strong year-to-date and 1-year returns.
Anika Therapeutics, Inc. (ANIK) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for Anika Therapeutics, Inc. (ANIK), including its current stock price, recent news, historical data, and analyst insights. The company, which specializes in early intervention orthopedics, shows a positive short-term stock performance but a significant decline over five years. Key financial metrics, earnings trends, and a company overview are also detailed.
Anika Therapeutics (NASDAQ:ANIK) Raised to Strong-Buy at Zacks Research
Zacks Research has upgraded Anika Therapeutics (NASDAQ:ANIK) to a "strong-buy" rating. This upgrade follows the company's strong quarterly earnings, where EPS of $0.42 significantly beat the $0.03 consensus, and revenue of $32.61 million also exceeded expectations. Institutional investors hold a substantial portion of the company's shares, and the stock is trading near its 52-week high after moving above key moving averages.
Anika Therapeutics, Inc. (ANIK) Stock Price, News, Quote & History
This article provides comprehensive financial data for Anika Therapeutics, Inc. (ANIK), including its current stock price, historical performance, and key financial metrics. It details the company's orthopedic products and services, analyst ratings, and comparative data with other companies in the drug manufacturing industry. The information aims to offer investors a detailed overview of ANIK's market position and financial health.
ANIK (NASDAQ: ANIK) holder plans Form 144 sale of 16,864 shares
An individual holder of Anika Therapeutics, Inc. (ANIK) plans to sell 16,864 shares of common stock on NASDAQ, with an aggregate market value of $355,255.47 as of August 7, 2026, according to a Form 144 filing. The filing also notes recent activity including an issuer open market purchase of 2,700 shares on March 5, 2024, and restricted stock vesting of 14,164 shares on June 20, 2026. This transaction provides transparency regarding the proposed sale of restricted securities.
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates
Anika Therapeutics Inc (ANIK) has an earnings forecast score of 9.00, placing it 7th in the Healthcare Equipment & Supplies industry. Analysts have a consensus "Strong Buy" rating with an average price target of $16.00. The company's expected revenue for the next quarter is $29.74 million, and the EPS for the next quarter is projected at $0.04.
Anika Therapeutics (ANIK) Insider Gary Fischetti Buys 2,000 Shares, Increasing Stake to 54,015 Shares
Gary Fischetti, a Director at Anika Therapeutics Inc (ANIK), recently purchased 2,000 shares at $20.53 each, increasing his total holdings to 54,015 shares. This transaction, valued at approximately $41,060, follows a trend of insider buying at the company, with 3 insider buys and no sells over the past year. Despite a mixed signal from guru ownership data, the insider's continued accumulation suggests confidence in the company's prospects, even though the stock is currently deemed "Fairly Valued" by GuruFocus's GF Value metric.
Anika Therapeutics (NASDAQ:ANIK) Director Purchases 1,000 Shares
Anika Therapeutics Director Gary Fischetti purchased 1,000 shares of ANIK stock for $20.75 each, increasing his direct ownership to 53,015 shares. This transaction follows strong quarterly earnings where Anika reported $0.42 EPS and $32.61 million in revenue, both exceeding analyst expectations. Despite institutional investors increasing their positions, the stock currently holds a consensus "Hold" rating with a $21.00 price target.
Anika Therapeutics (ANIK) director purchases 2,000 common shares in market buys
Anika Therapeutics director Gary P. Fischetti purchased a total of 2,000 shares of the company's common stock through open-market transactions on August 3 and 4, 2026. The purchases were made at per-share prices of $20.745 and $20.315, respectively. Following these transactions, Fischetti directly holds 54,015 shares of Anika Therapeutics common stock.
Anika Therapeutics Lifts Outlook After Margin Surge
Anika Therapeutics reported strong Q2 earnings, with record commercial and international revenue and significantly improved gross margins and adjusted EBITDA. The company raised its full-year guidance for revenue growth and adjusted EBITDA margin, despite acknowledging regulatory uncertainties for some products and potential quarterly variability in OEM sales. This positive performance has led to a more constructive outlook for the company's trajectory.
Q1 2025 Anika Therapeutics Inc Earnings Call Transcript
Anika Therapeutics Inc. (ANIK) reported mixed results for Q1 2025, with commercial channel revenue up 18% and regenerative solutions growing 33%, driven by the Integrity implant system. Strategic initiatives and cost-saving measures proved effective, with anticipated US approvals for Halofast and Singal expected to boost future performance. However, overall revenue declined 10% due to a 23% drop in the OEM channel from pricing pressure on Monovik and Orthovisk, leading to a 9-percentage-point decrease in gross margin and manufacturing challenges.
Anika Therapeutics Gains 29%, Insider Trades Reap Benefit
This article reports on Anika Therapeutics' significant stock gain of 29%. The rise in stock price has benefited company insiders who engaged in recent trades.
Vanguard Capital Management (ANIK) discloses 4.95% beneficial stake in Anika Therapeutics
Vanguard Capital Management LLC has reported a 4.95% beneficial ownership stake in Anika Therapeutics Inc (ANIK), amounting to 659,216 shares as of June 30, 2026. The filing indicates that Vanguard holds sole voting power over 87,103 shares and sole dispositive power over all 659,216 shares, with no shared voting or dispositive power. This investment reflects holdings across Vanguard funds and managed accounts, with no single other person having an interest exceeding 5% through these securities.
B. Riley Adjusts Anika Therapeutics Price Target to $21 From $18, Maintains Buy Rating
B. Riley has increased its price target for Anika Therapeutics (NASDAQ: ANIK) to $21 from $18, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook from the analyst firm regarding the company's future performance.
B. Riley Adjusts Anika Therapeutics Price Target to $21 From $18, Maintains Buy Rating
B. Riley has increased its price target for Anika Therapeutics (ANIK) to $21 from $18, while reaffirming its Buy rating on the stock. This adjustment reflects a positive outlook on the company, concurrent with Barrington also raising its price target to $21 and maintaining an Outperform rating. These analyst updates follow Anika Therapeutics' recent earnings report and revised guidance for the fiscal years 2026 and 2027.
Anika Therapeutics Inc (ANIK) Q2 2026 Earnings Call Highlights: Record Revenue and Margin ...
Anika Therapeutics Inc (ANIK) reported record Q2 2026 results, including a 17% increase in commercial channel revenue, a 65% gross margin, and record international revenue of $12.6 million. Adjusted EBITDA reached $7.1 million, and the company raised its full-year 2026 guidance. Despite these positive outcomes, potential challenges include revenue variability, pricing pressure in the OEM channel, uncertain regulatory approval for Hyalafast in the U.S., and lagging cash generation.
Anika Therapeutics 2Q Adj EPS 42c >ANIK
This article reports that Anika Therapeutics' adjusted earnings per share (EPS) for the second quarter were 42 cents. The headline provides the key financial performance indicator for the company.
Press Release: Anika Reports Second Quarter 2026 Financial Results
This press release from Anika reports their second quarter 2026 financial results. The document (although not provided) would contain key financial metrics and performance highlights for the period, offering insight into the company's fiscal health and operational achievements.
Anika Therapeutics Releases Q2 2026 Financial Results
Anika Therapeutics, Inc. reported a significant turnaround in Q2 2026, with adjusted earnings of $0.42 per share, exceeding expectations by 625.0%. The company's revenue increased by 16.0% to $32.6M, driven by strong growth in both its Commercial and OEM channels. This return to profitability marks an important milestone for Anika, operating in the joint preservation and orthopedics sector.
Anika Therapeutics Q2 2026 slides: margins surge, guidance raised
Anika Therapeutics reported Q2 2026 results that significantly exceeded analyst expectations, with adjusted earnings of $0.42 per share and revenue of $32.6 million. The company's shares surged on the news, driven by a successful operational transformation leading to expanded gross margins of 65% and raised full-year guidance for both revenue and adjusted EBITDA. Anika's strong performance across commercial and OEM channels, coupled with pipeline advancements and a robust financial position, signals continued growth despite potential challenges like pricing pressure and regulatory uncertainty for some products.
Anika Therapeutics Q2 2026: Revenue $32.6M, Gross Margin 65%, Net Income $3.3M
Anika Therapeutics reported strong Q2 2026 results, with revenue reaching $32.6 million, a 16% year-over-year increase, and a gross margin of 65%. The company achieved a net income of $3.3 million and adjusted diluted EPS of $0.42. Management raised its full-year 2026 revenue and adjusted EBITDA margin guidance, attributing success to record commercial and international channel revenues, along with operational improvements.
Anika Therapeutics Q2 revenue rises, lifts 2026 outlook
Anika Therapeutics reported a rise in its second-quarter revenue, leading the company to subsequently lift its financial outlook for 2026. This positive performance and improved forecast were highlighted in a Reuters news brief accessible via TradingView.
Anika: Q2 Earnings Snapshot
This article provides a second-quarter earnings snapshot for Anika. It contains no financial details or further information about the company's performance. The article is exceptionally brief, offering only a title without substantive content.
Anika Reports Second Quarter 2026 Financial Results
Anika Therapeutics, Inc. reported strong financial results for the second quarter of 2026, with total revenue increasing 16% year-over-year to $32.6 million, driven by record Commercial Channel revenue and strong OEM Channel performance. The company achieved $3.3 million in net income, a 65% gross margin, and $7.1 million in Adjusted EBITDA, leading to a raise in its full-year 2026 financial guidance. Anika also adopted a new revenue guidance practice, only including revenue from approved or cleared products, which impacted its 2027 Commercial Channel revenue forecast.
Anika Reports Second Quarter 2026 Financial Results
Anika Therapeutics, Inc. announced strong financial results for the second quarter of 2026, with total revenue reaching $32.6 million, an increase of 16% year-over-year, driven by record Commercial Channel revenue and strong OEM Channel performance. The company achieved a 65% gross margin and $7.1 million in Adjusted EBITDA, leading to a raise in its full-year 2026 financial guidance. Anika is also revising its 2027 revenue forecast to only include products with regulatory approval, reflecting ongoing regulatory processes for products like Hyalofast and Cingal.
Anika Reports Second Quarter 2026 Financial Results
Anika Therapeutics, Inc. announced strong financial results for the second quarter of 2026, with total revenue increasing to $32.6 million and a record $13.9 million in Commercial Channel revenue. The company reported $3.3 million in net income and $7.1 million in Adjusted EBITDA, leading to a raised full-year 2026 financial guidance. Anika also revised its 2027 revenue forecast, now only including revenue from approved or cleared products due to regulatory review uncertainties for Hyalofast.
Avoiding Lag: Real-Time Signals in (ANIK) Movement
An article by Stock Traders Daily's Quantitative Research Desk suggests that Anika Therapeutics Inc. (NASDAQ: ANIK) is facing weak near and mid-term sentiment, despite a positive long-term outlook. The analysis highlights a 34.4:1 risk-reward short setup, projecting a 10.9% downside risk versus a 0.3% risk. It outlines distinct trading strategies (Position Trading, Momentum Breakout, Risk Hedging) tailored for different risk profiles, along with multi-timeframe signal analysis indicating weak sentiment in the short and mid-term but strong sentiment in the long term for ANIK.
ANIK|Anika Therapeutics Inc|Price:15.010|Chg%:+0.060
This article provides a comprehensive financial overview of Anika Therapeutics Inc (ANIK), detailing its income statement, balance sheet, and cash flow statement. It highlights key financial indicators like EPS, Revenue, Net Profit, and margins across various quarters and years. The report also includes FAQs addressing specific financial metrics from the company's FY2025 earnings report.
ANIK|Anika Therapeutics Inc|Price:15.200|Chg%:+0.180
This article provides a comprehensive stock analysis of Anika Therapeutics Inc (ANIK) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. The analysis also notes high institutional ownership and a "Strong Buy" rating from multiple analysts, despite sideways stock price movement in the short term.
Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Anika Therapeutics Inc (ANIK) by business segment and geographical region. For the fiscal year 2025, the company's revenue was primarily driven by its OEM Channel and Commercial Channel. The United States contributed the largest portion of regional revenue, followed by Europe and other regions.
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Anika Therapeutics Inc (ANIK), highlighting its strong earnings forecast score and analyst ratings. It details the average price target, current analyst recommendations (Strong Buy), and compares ANIK with its peers in the Healthcare Equipment & Supplies industry. Key financial expectations for EPS and revenue are also included.
Anika Therapeutics (ANIK) Proxy filing Summary
Anika Therapeutics (ANIK) recently filed a proxy summary detailing proposed changes to its 2017 Omnibus Incentive Plan, particularly Proposal 4, which faces dilution concerns despite board approval. The plan continues to use a fungible design for executive compensation, assigning higher cost to full-value awards. Shareholders will vote on this and other matters, with the board recommending approval of the Seventh Amended Plan.
Anika Therapeutics, Inc. Revenue Breakdown – BX:AKP
This article provides a revenue breakdown for Anika Therapeutics, Inc. (AKP). Last year, the company generated 89.44M CHF, with its top-performing segment, Original Equipment Manufacturer Channel, contributing 51.06M CHF. The United States was the largest regional contributor, accounting for 55.54M CHF of the revenue.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics, Inc. announced it will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
Anika Therapeutics (ANIK) Proxy filing Summary
Anika Therapeutics (ANIK) achieved $112.8 million in 2025 revenue, driven by OA Pain Management, and generated $11.2 million in operating cash flow. The company’s strategic priorities for 2026 include accelerating commercial channel growth and advancing their HA-based pipeline. Key voting matters for shareholders include the election of three Class III Directors, ratification of Deloitte & Touche LLP as independent auditor, and approval of amendments to incentive and stock purchase plans.
Anika Therapeutics (ANIK) 2026 CG Musculoskeletal Conference Summary
Anika Therapeutics (ANIK) presented a summary of their 2026 CG Musculoskeletal Conference, detailing their strategy to accelerate growth through commercial momentum, product pipeline advancement, and operational discipline. The company highlighted its strong financial position, robust product portfolio in OA pain management and regenerative solutions, and upcoming regulatory milestones for Hyalofast and Cingal. Their strategy leverages differentiated hyaluronic acid-based technologies and aims for continued double-digit growth.
Anika Therapeutics (ANIK) AGM 2026 Summary
Anika Therapeutics held its 2026 Annual General Meeting (AGM) where the CEO and board members provided opening remarks and introduced key personnel. Five shareholder proposals were presented for approval, including the election of directors, ratification of Deloitte & Touche LLP as auditor, an advisory vote on executive compensation, and amendments to incentive and employee stock purchase plans. The board unanimously recommended approval for all proposals.
Anika Therapeutics (ANIK) Proxy filing Summary
Anika Therapeutics will present a revised proposal for its 2017 Omnibus Incentive Plan at the June 18, 2026 annual meeting, reducing the requested share reserve increase to 350,000 shares to address dilution concerns raised by Institutional Shareholder Services. The revised plan lowers potential dilution from 29.40% to 24.88% while maintaining strong governance features. The Board unanimously recommends shareholders vote "FOR" the amended plan.
BlackRock Portfolio Management (NASDAQ: ANIK) discloses 4.1% Anika Therapeutics ownership
BlackRock Portfolio Management LLC has filed an amended ownership report for Anika Therapeutics Inc. common stock, disclosing a 4.1% beneficial ownership stake, totaling 544,710 shares. The firm holds sole voting power over 520,622 shares and sole dispositive power over all 544,710 shares. No single client of BlackRock holds more than five percent of Anika's outstanding common stock.
Anika Therapeutics Expands Revolving Credit Facility Agreement
Anika Therapeutics announced it has expanded its revolving credit facility with Bank of America, N.A. The Fifth Amendment establishes a $50 million senior revolving line of credit with a new maturity date of July 10, 2031, and includes an option to increase total commitments to $100 million. This facility is secured by a first-priority lien on most of Anika's assets and features SOFR-based interest and commitment fees linked to its leverage ratio.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics Inc. will release its second-quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or live audio webcast on Anika's website.
Anika Therapeutics to issue Q2FY26 results on July 29
Anika Therapeutics, Inc. (NASDAQ: ANIK) is set to release its Q2FY26 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide business highlights. Investors can access the call via a toll-free or international number, with a live audio webcast and presentation materials available on the Investor Relations section of Anika's website.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the live audio webcast and presentation materials on the company's website.
Anika sets July 29 conference call for second-quarter results
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Following the release, management will host a conference call at 8:30 a.m. ET to discuss the results and business highlights, accessible via dial-in numbers and a live webcast. An archived replay and presentation materials will be available on the company's investor relations website.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Anika Therapeutics, Inc. announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights, with access details provided for both phone and webcast. The call and accompanying presentation materials will be available on Anika's investor relations website.
